Biological Testing Facility for Contraception Reproductive Health

The Biological Testing Facility for Contraception & Reproductive Health opportunity is a forecasted federal grant initiative administered by the National Institutes of Health under the U.S. Department of Health and Human Services, specifically through the Eunice Kennedy Shriver National Institute of Child Health and Human Development. This program is designed to support access to a specialized Biological Testing Facility that enables the advancement of contraceptive technologies and reproductive health-related product development. The initiative reflects a broader federal commitment to improving reproductive health outcomes and expanding contraceptive options for individuals across their reproductive lifespan. The purpose of this opportunity is to address a critical gap in the development pipeline for fertility regulation methods and reproductive therapies. The program encourages investigators who have already developed innovative and validated approaches to apply for access to testing infrastructure that can support further development toward clinical use. Rather than providing traditional direct funding for independent research projects, this opportunity uses the NIH X01 activity code, which is intended to grant access to NIH-supported research resources. This distinction is important, as it frames the award as a mechanism for utilizing federal infrastructure rather than receiving discretionary funding for general research purposes. The scope of the program includes biological testing services that support both contraceptive development and broader reproductive health innovations. While specific allowable cost categories are not detailed in the forecast notice, the nature of the X01 mechanism implies that awardees will receive access to facility resources rather than direct financial disbursements. There is no cost-sharing or matching requirement associated with this opportunity, which lowers the barrier to entry for eligible applicants and encourages participation from a diverse range of institutions and organizations. Eligibility for this opportunity is broad and inclusive, encompassing a wide range of public, private, nonprofit, and for-profit entities. Eligible applicants include federal agencies, state and local governments, tribal governments and organizations, institutions of higher education, small businesses, and nonprofit organizations regardless of 501(c)(3) status. Additionally, the program explicitly allows participation from foreign institutions and non-U.S. entities, indicating an international scope. Faith-based and community-based organizations are also eligible, further emphasizing the program’s inclusive approach to advancing reproductive health research. At the time of this forecast notice, applications are not yet being solicited. The announcement is intended to provide advance notice to potential applicants so they can prepare responsive proposals ahead of the official Notice of Funding Opportunity release. The estimated timeline indicates that the formal posting is expected in October 2025, with an anticipated application deadline in early January 2026. Awards are projected to be made in February 2026, with project activities beginning in March 2026. No pre-application requirements such as letters of intent or concept papers are specified in the forecast stage. The evaluation criteria and detailed submission requirements are not yet available, as they will be included in the forthcoming official funding announcement. However, applicants can reasonably expect that proposals will be assessed based on the scientific merit of their methods, relevance to contraceptive and reproductive health priorities, and readiness for further development using the Biological Testing Facility. Interested applicants are encouraged to monitor the official release and prepare materials accordingly. For additional information, potential applicants may contact the listed NIH program officer via email or phone to clarify program expectations and eligibility considerations.